Cipla shares ratings cut by Morgan Stanley, CLSA on earnings
- BJP calls Rahul's take on Land Bill a 'white lie', wants him to apologise
- Presstitutes remark row: Modi says media ignoring V K Singh's good work in Yemen
- This govt is for the poor: PM Modi to BJP MPs
- 51 arrested for setting Puri-Barbil Express train coach on fire
- COAI roots for net neutrality, access to Internet for all
Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd shares a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.